Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HistoSonics’ Edison System has received FDA clearance for non-invasive mechanical destruction of liver tumors. Clinical results from the #HOPE4LIVER trial showed 90% local tumor control at 12 months. The company is running additional trials for kidney cancer (#HOPE4KIDNEY) and has reported successful first-in-human treatments. Early-stage research is ongoing in other organ systems such as pancreas and prostate. The technology offers a non-invasive alternative to surgery or ablation with real-time imaging guidance, minimal complications, and rapid recovery times
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HistoSonics.